- Home
- ZGN vs DYN Comparison
ZGN vs DYN Comparison
Compare ZGN & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZGN | DYN |
|---|---|---|
| Founded | 1910 | 1984 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZGN | DYN |
|---|---|---|
| Price | $11.02 | $15.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | $11.28 | ★ $39.94 |
| AVG Volume (30 Days) | 839.8K | ★ 1.9M |
| Earning Date | 03-20-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $2,248,050,499.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.49 | N/A |
| P/E Ratio | $25.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.05 | $6.36 |
| 52 Week High | $11.29 | $25.00 |
Technical Indicators
Market Signals| Indicator | ZGN | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 34.33 |
| Support Level | $8.65 | $16.10 |
| Resistance Level | $10.98 | $17.45 |
| Average True Range (ATR) | 0.36 | 1.04 |
| MACD | 0.21 | -0.17 |
| Stochastic Oscillator | 90.53 | 0.90 |
Price Performance
Historical ComparisonAbout ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.